Multicenter Evaluation of a Novel Endothelial Cell Crossmatch Test in Kidney Transplantation

• DOI: 10.1097/tp.0b013e3181949d4e
• Publication Date: 2010-01-27T06:30:35Z
• Authors: Michael E. Breimer; Lennart Rydberg; Annette M. Jackson; Donna P. Lucas; Andrea A. Zachary; Joseph K. Melancon; Jon Von Visger; Ronald Pelletier; Susan L. Saidman; Winfred W. Williams; Jan Holgersson; Gunnar Tydén; Göran K. Klintmalm; Sonnya Coultrup; Suchitra Sumitran...; Per Grufman
• Keywords: Sweden; Histocompatibility Testing; Flow Cytometry; Kidney Transplantation; Receptor, TIE-2; United States; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Isoantibodies; Humans; Drug Therapy, Combination; Endothelium, Vascular; Immunosuppressive Agents

Background. Despite their clinical importance, routine tests to detect anti-endothelial cell antibodies (AECA) in organ transplantation have not been readily available. This multicenter prospective kidney trial evaluates the efficacy of a novel endothelial crossmatch (ECXM) test donor-reactive AECA associated with allograft rejection. Methods. Pretransplant serum samples from 147 patients were tested for by flow cytometric technique (XM-ONE) using peripheral blood progenitor cells as targets. Patient enrolment was based on acceptance determined donor lymphocyte results. Results. Donor-reactive found 35 (24%) patients. A significantly higher proportion positive ECXM had rejections (16 35, 46%) during follow-up at least 3 months compared those without (13 112, 12%; P<0.00005). Both IgG and IgM AECAs graft rejections. Mean creatinine levels 6 posttransplant. Conclusions. XM-ONE is quick, easy perform whole identifies risk rejection reduced function identified conventional crossmatches.